Home LiteratureArticle Details
PMID: 30861269 Published · ppublish English Journal Article

Immune infiltration in renal cell carcinoma.

Cancer science ·Vol. 110 ·No. 5 ·2019-05-00 ·Pages 1564-1572

Zhang S, Zhang E, Long J, Hu Z, Peng J, Liu L, Tang F, Li L, Ouyang Y, Zeng Z

Abstract

Immune infiltration of tumors is closely associated with clinical outcome in renal cell carcinoma (RCC). Tumor-infiltrating immune cells (TIICs) regulate cancer progression and are appealing therapeutic targets. The purpose of this study was to determine the composition of TIICs in RCC and further reveal the independent prognostic values of TIICs. CIBERSORT, an established algorithm, was applied to estimate the proportions of 22 immune cell types based on gene expression profiles of 891 tumors. Cox regression was used to evaluate the association of TIICs and immune checkpoint modulators with overall survival (OS). We found that CD8+ T cells were associated with prolonged OS (hazard ratio [HR] = 0.09, 95% confidence interval [CI].01-.53; P = 0.03) in chromophobe carcinoma (KICH). A higher proportion of regulatory T cells was associated with a worse outcome (HR = 1.59, 95% CI 1.23-.06; P < 0.01) in renal clear cell carcinoma (KIRC). In renal papillary cell carcinoma (KIRP), M1 macrophages were associated with a favorable outcome (HR = .43, 95% CI .25-.72; P < 0.01), while M2 macrophages indicated a worse outcome (HR = 2.55, 95% CI 1.45-4.47; P < 0.01). Moreover, the immunomodulator molecules CTLA4 and LAG3 were associated with a poor prognosis in KIRC, and IDO1 and PD-L2 were associated with a poor prognosis in KIRP. This study indicates TIICs are important determinants of prognosis in RCC meanwhile reveals potential targets and biomarkers for immunotherapy development.

Keywords
genomic alterations overall survival prognosis renal cell carcinoma tumor-infiltrating immune cells
MeSH Terms
Algorithms Antigens, CD/metabolism CD8-Positive T-Lymphocytes/metabolism CTLA-4 Antigen/metabolism Carcinoma, Papillary/immunology,metabolism,pathology Carcinoma, Renal Cell/immunology,metabolism,pathology Female Humans Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism Kidney Neoplasms/immunology,metabolism,pathology Lymphocytes, Tumor-Infiltrating/metabolism Macrophages/metabolism Male Neoplasm Staging Prognosis Programmed Cell Death 1 Ligand 2 Protein/metabolism Survival Analysis T-Lymphocytes, Regulatory/metabolism
Chemicals
Antigens, CD CD223 antigen CTLA-4 Antigen IDO1 protein, human Indoleamine-Pyrrole 2,3,-Dioxygenase PDCD1LG2 protein, human Programmed Cell Death 1 Ligand 2 Protein
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Zhang Shichao ORCID
Immune Cells and Antibody Engineering Research Center of Guizhou Province/Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, China. | School of Biology and Engineering, Guizhou Medical University, Guiyang, China.
Zhang Erdong
School of Life Sciences, Lanzhou University, Lanzhou, China.
Long Jinhua
Affiliated Tumor Hospital, Guizhou Medical University, Guiyang, China.
Hu Zuquan
Immune Cells and Antibody Engineering Research Center of Guizhou Province/Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, China. | School of Biology and Engineering, Guizhou Medical University, Guiyang, China.
Peng Jian
Immune Cells and Antibody Engineering Research Center of Guizhou Province/Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, China. | School of Biology and Engineering, Guizhou Medical University, Guiyang, China.
Liu Lina
Immune Cells and Antibody Engineering Research Center of Guizhou Province/Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, China. | School of Biology and Engineering, Guizhou Medical University, Guiyang, China.
Tang Fuzhou
Immune Cells and Antibody Engineering Research Center of Guizhou Province/Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, China. | School of Biology and Engineering, Guizhou Medical University, Guiyang, China.
Li Long
Department of Nephrology, The Third Affiliated Hospital of Guizhou Medical University, Duyun, China.
Ouyang Yan
Immune Cells and Antibody Engineering Research Center of Guizhou Province/Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, China. | School of Biology and Engineering, Guizhou Medical University, Guiyang, China.
Zeng Zhu
Immune Cells and Antibody Engineering Research Center of Guizhou Province/Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, China. | School of Biology and Engineering, Guizhou Medical University, Guiyang, China. | School of Basic Medical Science, Guizhou Medical University, Guiyang, China.
References (44)
44 references, click to expand
  1. Immune infiltration in renal cell carcinoma.
    Cancer Sci. 2019 May;110(5):1564-1572 PMID: 30861269
  2. Treatment of renal cell carcinoma: Current status and future directions.
    CA Cancer J Clin. 2017 Nov;67(6):507-524 PMID: 28961310
  3. G0S2 modulates homeostatic proliferation of naïve CD8⁺ T cells and inhibits oxidative phosphorylation in mitochondria.
    Immunol Cell Biol. 2015 Aug;93(7):605-15 PMID: 25666096
  4. Resident memory T cells, critical components in tumor immunology.
    J Immunother Cancer. 2018 Sep 4;6(1):87 PMID: 30180905
  5. Systemic Therapy for Metastatic Renal-Cell Carcinoma.
    N Engl J Med. 2017 Jan 26;376(4):354-366 PMID: 28121507
  6. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer.
    Am J Transl Res. 2012;4(4):376-89 PMID: 23145206
  7. Tumor-associated macrophages: from mechanisms to therapy.
    Immunity. 2014 Jul 17;41(1):49-61 PMID: 25035953
  8. Effector CD8 T cells dedifferentiate into long-lived memory cells.
    Nature. 2017 Dec 21;552(7685):404-409 PMID: 29236683
  9. Overexpression of low density lipoprotein receptor-related protein 1 (LRP1) is associated with worsened prognosis and decreased cancer immunity in clear-cell renal cell carcinoma.
    Biochem Biophys Res Commun. 2018 Sep 10;503(3):1537-1543 PMID: 30033103
  10. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
    N Engl J Med. 2015 Nov 5;373(19):1803-13 PMID: 26406148
  11. Intratumoral T cells, tumor-associated macrophages, and regulatory T cells: association with p53 mutations, circulating tumor DNA and survival in women with ovarian cancer.
    Gynecol Oncol. 2008 May;109(2):215-9 PMID: 18314181
  12. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.
    Am J Surg Pathol. 2013 Oct;37(10):1469-89 PMID: 24025519
  13. Phenotypical change of tumor-associated macrophages in metastatic lesions of clear cell renal cell carcinoma.
    Med Mol Morphol. 2018 Mar;51(1):57-63 PMID: 29218457
  14. Immune Infiltration in Invasive Lobular Breast Cancer.
    J Natl Cancer Inst. 2018 Jul 1;110(7):768-776 PMID: 29471435
  15. Checkpoint molecule PD-1-assisted CD8+ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
    Cancer Manag Res. 2018 Sep 11;10:3419-3431 PMID: 30237743
  16. Robust enumeration of cell subsets from tissue expression profiles.
    Nat Methods. 2015 May;12(5):453-7 PMID: 25822800
  17. Recent progress in the management of advanced renal cell carcinoma.
    CA Cancer J Clin. 2007 Mar-Apr;57(2):112-25 PMID: 17392388
  18. Macrophages and cancer: from mechanisms to therapeutic implications.
    Trends Immunol. 2015 Apr;36(4):229-39 PMID: 25770924
  19. CD4 + T cells promote renal cell carcinoma proliferation via modulating YBX1.
    Exp Cell Res. 2018 Feb 1;363(1):95-101 PMID: 29289594
  20. Macrophage polarization in tumour progression.
    Semin Cancer Biol. 2008 Oct;18(5):349-55 PMID: 18467122
  21. An Immune Atlas of Clear Cell Renal Cell Carcinoma.
    Cell. 2017 May 4;169(4):736-749.e18 PMID: 28475899
  22. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.
    Cell. 2018 Oct 4;175(2):313-326 PMID: 30290139
  23. CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.
    Curr Opin Chem Eng. 2018 Mar;19:9-20 PMID: 29623254
  24. Hepatocyte-Specific Arid1a Deficiency Initiates Mouse Steatohepatitis and Hepatocellular Carcinoma.
    PLoS One. 2015 Nov 16;10(11):e0143042 PMID: 26569409
  25. Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.
    Sci Rep. 2018 Apr 18;8(1):6220 PMID: 29670256
  26. Development of T follicular helper cells and their role in disease and immune system.
    Biomed Pharmacother. 2016 Dec;84:1668-1678 PMID: 27863842
  27. T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview.
    Biomed Res Int. 2015;2015:327470 PMID: 26583100
  28. Immune cell promotion of metastasis.
    Nat Rev Immunol. 2015 Feb;15(2):73-86 PMID: 25614318
  29. Natural innate and adaptive immunity to cancer.
    Annu Rev Immunol. 2011;29:235-71 PMID: 21219185
  30. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.
    Immunity. 2016 Mar 15;44(3):698-711 PMID: 26982367
  31. Targeting CXCR4 reverts the suppressive activity of T-regulatory cells in renal cancer.
    Oncotarget. 2017 Aug 19;8(44):77110-77120 PMID: 29100374
  32. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.
    J Pathol. 2014 Jan;232(2):199-209 PMID: 24122236
  33. Macrophage activation and polarization: nomenclature and experimental guidelines.
    Immunity. 2014 Jul 17;41(1):14-20 PMID: 25035950
  34. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
    Cell Rep. 2017 Jan 3;18(1):248-262 PMID: 28052254
  35. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.
    PLoS Med. 2016 Dec 13;13(12):e1002194 PMID: 27959923
  36. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity.
    Eur Urol. 2015 Jan;67(1):85-97 PMID: 24857407
  37. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
    Immunity. 2013 Oct 17;39(4):782-95 PMID: 24138885
  38. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Hepatology. 2015 May;61(5):1591-602 PMID: 25529917
  39. Molecular and cellular insights into T cell exhaustion.
    Nat Rev Immunol. 2015 Aug;15(8):486-99 PMID: 26205583
  40. The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer.
    Biomed Pharmacother. 2017 Nov;95:55-61 PMID: 28826097
  41. EAU guidelines on renal cell carcinoma: 2014 update.
    Eur Urol. 2015 May;67(5):913-24 PMID: 25616710
  42. Immunity, inflammation, and cancer.
    Cell. 2010 Mar 19;140(6):883-99 PMID: 20303878
  43. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
    J Clin Invest. 2016 Sep 1;126(9):3447-52 PMID: 27525433
  44. Regulatory circuits of T cell function in cancer.
    Nat Rev Immunol. 2016 Oct;16(10):599-611 PMID: 27526640
Article Info
Journal
Cancer science
Abbr.
Cancer Sci
ISSN
1349-7006
Published
2019-05-00
Epub
2019-00-07
Pages
1564-1572
Language
English
Region
England
NLM ID
101168776
PMCID
PMC6501001
Subset
IM
Grants
National Natural Science Foundation of China · 11762006
National Natural Science Foundation of China · 31760264
National Natural Science Foundation of China · 31771014
National Natural Science Foundation of China · 31860244
Doctoral Scientific Research Foundation of Guizhou Medical University · YJ2017-30
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com